Pediatric candidates were predominantly complex, with severe corneal pathology and 6/11 eyes having preexisting glaucoma, ...

The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...

A retrospective cohort of 15,045 Down syndrome patients with septal defects and 15,045 without enabled comparative risk estimation for multiple ocular outcomes over 2-, 5-, and 10-year horizons.

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

Renee Bovelle, MD: I am thrilled and humbled to be the first physician to lead OWL. It is a deep honor and a meaningful responsibility.

In this episode of the NeuroOp Guru in collaboration with Ophthalmology Times, host Andrew G. Lee, MD, is joined by Drew Carey, MD, to discuss pretreatment features associated with vision improvement ...

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...

A study from 7 institutions in Hong Kong reported that tapering of low-dose atropine before the drug was discontinued had ...

Adam Jacobson, MD, and colleagues retrospectively investigated how glaucoma affects the eyes of pediatric patients with ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...